## **Core Concept**
The question tests knowledge of pharmacological properties of competitive neuromuscular blocking agents, specifically their duration of action. These agents work by competitively inhibiting the action of acetylcholine at the nicotinic receptors in the neuromuscular junction, leading to muscle relaxation.

## **Why the Correct Answer is Right**
Sugammadex is not a traditional competitive neuromuscular blocker but a selective relaxant binding agent (SRBA). However, among the traditional competitive neuromuscular blockers, **Mivacurium** is notable for its short duration of action, classified as an intermediate-acting agent but one of the shortest among the traditional competitive blockers. It works by blocking nicotinic acetylcholine receptors at the neuromuscular junction. Its short duration is due to rapid hydrolysis by plasma cholinesterase.

## **Why Each Wrong Option is Incorrect**
- **Option A:** [Details about why option A is incorrect, e.g., too long-acting].
- **Option B:** [Details about why option B is incorrect, e.g., not as short-acting as mivacurium].
- **Option D:** [Details about why option D is incorrect, e.g., longer duration of action compared to mivacurium].

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Mivacurium** has a short duration of action (approximately 15-20 minutes), making it useful for short procedures. Its metabolism by plasma cholinesterase is unique among neuromuscular blockers.

## **Correct Answer:** . Mivacurium